Pharming Group (PHGUF) to Release Quarterly Earnings on Thursday

Key Points

• Pharming Group will report quarterly results before the market opens on Thursday, May 7, with analysts forecasting EPS $0.0007 and $93.75 million in revenue.
• In the prior quarter (reported March 12) Pharming posted EPS $0.01 and $106.5 million in revenue, beating estimates of $89.72 million, with a net margin of 0.71% and ROE of 1.08%.
• PHGUF stock opened at $1.75 with a market cap of $1.17 billion and a PE of 175.18; the 52-week range is $0.89–$2.17 and the company shows healthy liquidity (current ratio 2.59) and a debt-to-equity of 0.39.

Pharming Group (OTCMKTS:PHGUF - Get Free Report) is expected to be issuing its results before the market opens on Thursday, May 7th. Analysts expect the company to announce earnings of $0.0007 per share and revenue of $93.75 million for the quarter.

Pharming Group (OTCMKTS:PHGUF - Get Free Report) last posted its earnings results on Thursday, March 12th. The biotechnology company reported $0.01 earnings per share for the quarter. Pharming Group had a net margin of 0.71% and a return on equity of 1.08%. The firm had revenue of $106.50 million during the quarter, compared to analyst estimates of $89.72 million.

Pharming Group Stock Performance

PHGUF stock opened at $1.75 on Thursday. The firm has a fifty day moving average price of $1.60 and a 200 day moving average price of $1.65. Pharming Group has a fifty-two week low of $0.89 and a fifty-two week high of $2.17. The company has a debt-to-equity ratio of 0.39, a quick ratio of 2.03 and a current ratio of 2.59. The firm has a market cap of $1.17 billion, a PE ratio of 175.18 and a beta of 0.45.

About Pharming Group

Pharming Group NV is a Netherlands-based biopharmaceutical company specializing in the development and commercialization of protein replacement therapies for rare diseases. Founded in 1988 and headquartered in Leiden, the company leverages transgenic technology to produce recombinant proteins, with its flagship product RUCONEST (recombinant C1 esterase inhibitor) indicated for the treatment of acute hereditary angioedema (HAE) attacks. RUCONEST is approved and marketed in the United States, Europe and several other territories through partnerships with leading specialty pharmaceutical companies.

Beyond RUCONEST, Pharming maintains a diversified pipeline targeting unmet needs in rare and ultra-rare disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.